Key statistics
As of last trade aTyr Pharma Inc (471A:DEU) traded at 2.86, -15.88% below its 52-week high of 3.40, set on Oct 29, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.80 |
---|---|
High | 2.92 |
Low | 2.72 |
Bid | 2.86 |
Offer | 2.96 |
Previous close | 2.88 |
Average volume | 1.16k |
---|---|
Shares outstanding | 75.80m |
Free float | 65.84m |
P/E (TTM) | -- |
Market cap | 236.48m USD |
EPS (TTM) | -0.9047 USD |
Data delayed at least 15 minutes, as of Nov 08 2024.
More ▼
Announcements
- aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update
- aTyr Pharma to Present at Upcoming Investor Conferences
- aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
- aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal
- aTyr Pharma to Participate in September Investor Conferences
- aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update
- aTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical Operations
- aTyr Pharma Announces Research Study with Stanford Medicine
- aTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis
- aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
More ▼